NCT05126979 is a Phase 1 clinical trial of Inactivated Split Influenza Vaccine in Influenza, sponsored by St. Petersburg Research Institute of Vaccines and Sera.

Who is sponsoring NCT05126979?

NCT05126979 is sponsored by St. Petersburg Research Institute of Vaccines and Sera.

What drugs are being tested in NCT05126979?

Interventions in NCT05126979: Inactivated Split Influenza Vaccine, Placebo.

Is NCT05126979 still recruiting?

NCT05126979 is currently completed. Last updated 6 January 2022.

Last reviewed 2022-01-06 · How we verify

NCT05126979

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Objectives of This Study Are Study of the Reactogenicity, Safety and Immunogenicity of Flu-M Inactivated Split Influenza Vaccine in Volunteers Aged 18-60 Years

Completed Phase 1 Last updated 6 January 2022

What this trial tests

Phase 1 trial testing Inactivated Split Influenza Vaccine in Influenza in 45 participants. Completed in 13 May 2016.

Timeline

9 March 2016

Primary endpoint
25 April 2016

13 May 2016

Quick facts

Lead sponsor	St. Petersburg Research Institute of Vaccines and Sera
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	45
Start date	9 March 2016
Primary completion	25 April 2016
Estimated completion	13 May 2016
Sites	1 location across Russia

Drugs / interventions tested

Inactivated Split Influenza Vaccine — full drug profile →
Placebo

Conditions studied

Influenza — all drugs for Influenza →

Sponsor

St. Petersburg Research Institute of Vaccines and Sera

Who can join

Adults 18 to 60, any sex, with Influenza. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study of the Reactogenicity, Safety and Immunogenicity of Flu-M Inactivated Split Influenza Vaccine in Volunteers Aged 18-60 Years

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Inactivated Split Influenza Vaccine

Trials testing the same drug.

NCT05089123 — The Objectives of This Study Are Study the Immunogenicity and Safety of the Flu-M [Inactivated Split Influenza Vaccine], · Phase 3 · completed
NCT05317767 — The Objectives of This Study Are Comparative Assessment of the Tolerability, Safety and Immunogenicity of the Flu-M Vacc · Phase 3 · completed

Other recruiting trials for Influenza

Currently open trials in the same condition.

NCT07215858 — BPL-1357 Against H1N1 Influenza Virus Challenge · Phase 2 · recruiting
NCT07496450 — A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults · Phase 3 · recruiting
NCT07302256 — A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above · Phase 1 · recruiting
NCT07431840 — Immune Defense Protein Impact On Respiratory Immune Outcomes · NA · recruiting
NCT07485855 — Influenza Vaccination Strategy for Patients With Hematologic Malignancy · Phase 3 · recruiting

Other St. Petersburg Research Institute of Vaccines and Sera trials

Trials by the same sponsor.

NCT05726084 — Immunogenicity, Efficacy and Safety Trial of the Convacell Vaccine in Healthy Volunteers Aged 18 Years and Older · Phase 2, PHASE3 · unknown
NCT05739474 — Tolerability, Safety and Immunogenicity Trial of the Flu-M Tetra Vaccine in Children · Phase 3 · unknown
NCT05156723 — Study of the Immunogenicity, Safety and Tolerability of the Convacell Vaccine. · Phase 1, PHASE2 · completed
NCT05308212 — Tolerability, Safety and Immunogenicity Trial of the FLU-M® Tetra · Phase 2, PHASE3 · completed
NCT05470582 — Trial of Tolerability, Safety and Immunogenicity of the Flu-M Vaccine in Children Between 6 Months and 9 Years Old · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05126979 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by St. Petersburg Research Institute of Vaccines and Sera
Last refreshed: 6 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05126979.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing